Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zanzalintinib
- Development stage
- Phase 3
- Lead developer
- Exelixis
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Zanzalintinib is an orally bioavailable, next-generation small molecule tyrosine kinase inhibitor (TKI) that targets multiple receptor tyrosine kinases implicated in tumor angiogenesis, metastasis, and immunosuppression. Its primary molecular targets include hepatocyte growth factor receptor (c-Met; HGFR), vascular endothelial growth factor receptor type 2 (VEGFR2), and the TAM family kinases AXL and MER. By inhibiting these kinases, zanzalintinib blocks key signaling pathways involved in tumor cell proliferation, survival, invasion, angiogenesis, metastasis, and immune evasion. This results in antiangiogenic and antineoplastic effects as well as modulation of the tumor immune microenvironment. Zanzalintinib is being developed by Exelixis for use primarily in advanced or metastatic renal cell carcinoma—including both clear cell (ccRCC) and non-clear-cell subtypes—as well as colorectal cancer (CRC) and squamous cell carcinoma of the head and neck (SCCHN). It is currently under investigation in phase 3 clinical trials both as monotherapy and in combination with immune checkpoint inhibitors[1][2][4][5][6][7].
- Brand names
- Zanzalintinib
- Other names
- zanzalintinib
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)AXL (AXL receptor tyrosine kinase)MERTK (MER proto-oncogene, tyrosine kinase)MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on zanzalintinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zanzalintinib.